The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index; 29 of the 147 sources its claims cite were checked for support.
The biological and clinical significance of emerging SARS-CoV-2 variants
Open accessAbstract
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic. These variants can increase rates of virus transmission and/or increase the risk of reinfection and reduce the protection afforded by neutralizing monoclonal antibodies and vaccination. These variants can therefore enable SARS-CoV-2 to continue its spread in the face of rising population immunity while maintaining or increasing its replication fitness. The identification of four rapidly expanding virus lineages since December 2020, designated variants of concern, has ushered in a new stage of the pandemic. The four variants of concern, the Alpha variant (originally identified in the UK), the Beta variant (originally identified in South Africa), the Gamma variant (originally identified in Brazil) and the Delta variant (originally identified in India), share several mutations with one another as well as with an increasing number of other recently identified SARS-CoV-2 variants. Collectively, these SARS-CoV-2 variants complicate the COVID-19 research agenda and necessitate additional avenues of laboratory, epidemiological and clinical research. In this Review, the authors describe our latest understanding of the emergence and properties of SARS-CoV-2 genetic variants, particularly those designated as WHO (World Health Organization) ‘variants of concern’. They focus on the consequences of these variants for antibody-mediated virus neutralization, with important implications for reinfection risk and for vaccine effectiveness.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review synthesizes SARS-CoV-2 evolution, spike structure and the biological/clinical significance of the four WHO variants of concern as of June 2021: Alpha, Beta, Gamma and Delta. It shows that recurrent spike mutations increase transmissibility and immune evasion, reducing neutralization by monoclonal antibodies and vaccinee plasma, and calls for integrated genomic, neutralization and vaccine-efficacy surveillance.
Key findings
- Four VOCs emerged independently: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). Alpha was estimated to be ~50% more transmissible than prior UK variants and associated with an estimated 50% increased mortality; Beta was estimated to be 50% more transmissible than preceding lineages; Gamma was estimated to cause 3–4 times higher virus levels and 1.1-fold to 1.8-fold higher mortality; Delta spread to 54 countries and replaced Alpha in the UK and USA.
- Neutralization escape varied by variant. Beta showed 3-fold to 10-fold reduced susceptibility to 46% and >10-fold reduced susceptibility to 22% of convalescent plasma samples; mRNA vaccinee plasma showed 45% with 3-fold to 10-fold and 30% with >10-fold reduced Beta neutralization. Delta showed 3-fold to 10-fold reduced susceptibility to 45% and >10-fold to 5% of convalescent plasma samples, while ~15% of BNT162b vaccinee plasma had 3-fold to 10-fold reduced Delta neutralization. Alpha was rarely associated with reduced convalescent plasma susceptibility but showed 3-fold to 10-fold reduced susceptibility to ~15% of mRNA vaccinee plasma samples.
- Vaccine efficacy against VOCs was reduced in several studies: BNT162b retained >90% efficacy against Alpha in Israel and Qatar; Beta efficacy was 72% in a Qatar cohort and 75% in a test-negative case-control study; Delta efficacy was ~85% for BNT162b and ~60% for AZD1222 in UK case-control studies. In trials, AZD1222 efficacy against Beta was 10% in South Africa, and NVX-CoV2373 efficacy was 49% against Beta and 86.3% against Alpha versus 96.4% against non-Alpha variants.
- Key mutations include D614G, which rose to near 100% global prevalence by June 2020; N501Y, which increases ACE2 affinity; E484K, which reduces susceptibility to several monoclonal antibodies and plasma; and non-spike mutations that antagonize innate immunity, with Alpha and Beta showing mean 112-fold and 8-fold reduced susceptibility to type I interferons, respectively, compared with an early pandemic virus.
Methods
- Narrative review creating a framework for SARS-CoV-2 variants by describing evolution, spike protein structure/function, laboratory characterization methods, biological and epidemiological properties of VOCs/VOIs, and required research responses; data summarized as of June 2021.
- Synthesizes genomic surveillance data from more than two million partially or fully sequenced virus isolates, in vitro selection and neutralization experiments using pseudotyped viruses, VSV-based chimeric viruses, full-length recombinant SARS-CoV-2 and cultured isolates, deep mutational scanning, and vaccine efficacy trials, test-negative case-control studies and cohort studies.
- Neutralization results were pooled in the Stanford University Coronavirus Antiviral & Resistance Database and summarized as <3-fold, 3–10-fold and >10-fold reductions compared with control viruses.
Limitations
- The paper states that as of June 2021 it is uncertain whether current lineage-based variant classification will be sustainable, and that classifying variants by component mutations may become challenging if recurrent mutations increase.
- The paper notes unresolved questions, including whether neutralizing antibodies are the most important protective mechanism versus memory B cells, Fc-effector functions and T cell immunity, and whether updated immunogens can broaden responses in animal models more predictive of humans.
- Evident from the text: this is a synthesis as of June 2021, so later variants and data are not included; neutralization estimates pool results across pseudotyped, chimeric and infectious virus assays, and some distributions are approximate because they include results reported only as aggregate mean fold reductions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
65 Not checked yet · 10 Partly supported · 10 Own interpretation · 3 No basis given · 1 Supported · 1 Mixed support · accuracy not yet measured
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Among plasma samples obtained from recipients of the BNT162b vaccine, approximately 15% displayed 3-fold to 10-fold reduced neutralizing activity against the Delta variant 100,118,214 (fIg.5).”
What the sources say
- Partly supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). sourceExperimental — accuracy not yet measured
The Results section ('Protection from B.1.617.1 and B.1.617.2 by vaccine serum'; page not provided) reports reduced neutralization of Delta (B.1.617.2) by serum from BNT162b2 recipients. It gives a 2.5-fold reduction in geometric mean titer across 25 samples, but does not report that approximately 15% of samples had 3-fold to 10-fold reductions. (LLM, conf=0.88)
- Disputedcites [118] Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). sourceExperimental — accuracy not yet measured
The Article (p. 2) reports a geometric mean titre of 502 against wild-type virus and 355 against B.1.617.2 (Delta), describing the reduction as modest. The individual results in Extended Data Table 1 (p. 8) show no Delta titre 3- to 10-fold lower than its paired wild-type titre, contrary to the claimed 15% of samples. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that antibodies elicited by the Pfizer and AstraZeneca vaccines were about three- to fivefold less potent against Delta than Alpha. The section ‘Sensitivity of Delta to sera from vaccinated individuals’ (page unavailable) reports that 13% of Pfizer recipients’ sera neutralized Delta after one dose, not that approximately 15% showed a three- to tenfold reduction. The claimed sample proportion and full reduction range are not supported. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in three other studies, the median reduction in neutralizing activity was between onefold and threefold 102,214,215 .”
What the sources say
- Partly supportedcites [102] Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211 (2021). sourceExperimental — accuracy not yet measured
The Results section ('Neutralization activity of convalescent plasma and vaccine sera'; page not provided) reports a 2.9-fold reduction for convalescent plasma and 2.1- and 2.5-fold reductions for AstraZeneca vaccine sera, all within the claimed range. These are geometric means, not medians, and the reported Pfizer vaccine-serum reduction is 3.3-fold, outside that range. This source cannot establish the results of the other two cited studies. (LLM, conf=0.85)
- Supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). source
In “Sensitivity of Delta to convalescent sera” (page unavailable), the paper reports median neutralization titres and says Delta titres were fourfold lower than Alpha titres and sixfold lower than D614G titres. Those comparisons imply an approximately 1.5-fold reduction for Alpha relative to D614G, within the claimed onefold-to-threefold range. This paper is one of the three studies cited; it need not itself report the other two. (LLM, conf=0.84)
- Not checked yetcites [215] Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. Preprint at Research Square https://www.researchsquare.com/article/rs-637724/v1 (2021).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of plasma samples obtained from persons receiving one of the mRNA vaccines, 45% had 3-fold to 10-fold and 30% had >10-fold reduced Beta variant neutralizing activity 97,104,117,121,151,204,208,209,222,223 (fIg.5).”
What the sources say
- Not checked yetcites [97] Chen, X. et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab646 (2021). This paper presents a systematic review and meta-analysis of in vitro neutralization studies of SARS-CoV-2 variants by convalescent and vaccinee plasma. source
- Partly supportedcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). sourceExperimental — accuracy not yet measured
The Results section, “Neutralization of B.1.351 by vaccinee serum” (page unavailable), reports that serum from Pfizer-BioNTech vaccine recipients had a 7.6-fold lower geometric mean neutralization titer against B.1.351 than against Victoria. It does not report that 45% of mRNA-vaccine samples had a 3- to 10-fold reduction or that 30% had a greater-than-10-fold reduction. (LLM, conf=0.88)
- Partly supportedcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). sourceExperimental — accuracy not yet measured
The Results report reduced neutralization of the Beta (B.1.351) variant by sera from BNT162b2 mRNA-vaccine recipients: a 10-fold reduction in geometric mean activity in one assay and a 6- to 9-fold reduction in another. They do not report the claimed distribution of samples—45% with 3- to 10-fold reductions and 30% with reductions greater than 10-fold—or results from more than one mRNA vaccine. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Among the FDA EUA-approved mAbs, the Delta variant is associated with high-level reduced bamlanivimab susceptibility 100,214 .”
What the sources say
- Supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
In Results, under “Neutralization of B.1.617.1 and B.1.617.2 by mAbs developed for clinical use” (page unavailable), the paper reports that LY-CoV555 (bamlanivimab) had severely reduced neutralization of B.1.617.2 (Delta). The section also describes the tested antibodies as clinical-use mAbs, some of which had received emergency use authorization. (LLM, conf=0.88)
- Supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). source
The ‘Neutralization of Delta by antibodies’ section identifies bamlanivimab among the clinically approved monoclonal antibodies tested. The paper reports that Delta resisted neutralization by bamlanivimab, and the Article section states that bamlanivimab no longer bound to Delta-infected cells. These findings support high-level reduced susceptibility; the copy does not specify FDA EUA status. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By contrast, among plasma samples obtained from recipients of the AZD1222 vaccine, higher proportions displayed reduced neutralizing activity against this variant 100,209,214 .”
What the sources say
- Partly supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). sourceExperimental — accuracy not yet measured
The Results section, “Protection from B.1.617.1 and B.1.617.2 by vaccine serum” (page unavailable), reports that neutralization titers in serum from Oxford-AstraZeneca (AZD1222) recipients were 4.3-fold lower against B.1.617.2 (Delta) than against the Victoria strain. That supports reduced neutralizing activity, but the passage reports a reduction in the group's geometric mean titer, not a higher proportion of individual samples showing reduced activity. (LLM, conf=0.83)
- Partly supportedcites [209] Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331–2333 (2021). sourceExperimental — accuracy not yet measured
The main text (page not given; appendix p. 2 cited) reports that a higher proportion of samples from BNT162b2 recipients had low neutralising titres against B.1.617.2 (Delta) than against wild-type virus. It does not report this result for AZD1222 recipients; searches for AZD1222 and ChAdOx1 found no such analysis in our copy. (LLM, conf=0.86)
- Partly supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). sourceExperimental — accuracy not yet measured
In “Sensitivity of Delta to sera from vaccinated individuals,” the paper reports that after one AstraZeneca (AZD1222) dose, only 9% of recipients’ sera neutralized Delta, compared with 74% for D614G and 61% for Alpha. The claim omits the dose qualification: four weeks after a second dose, sera from 95–100% of AstraZeneca recipients neutralized all four strains. The paper tested sera, rather than describing the samples as plasma. (LLM, conf=0.86)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The past several months have witnessed the emergence of four SArS-cov-2 variants of concern (Alpha, beta, Gamma and Delta)”
- Also stated in: § SARS-CoV-2 evolution · plain
“The four variants of concern, the Alpha variant (originally identified in the UK), the Beta variant (originally identified in South Africa), the Gamma variant (originally identified in Brazil) and the Delta variant (originally identified in India)”
What the sources say
- Not checked yetcites [27] Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological https://virological.org/t/563 (2020).
- Not checked yetcites [16] Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021). This molecular epidemiological study charts the spread of the beta variant in South Africa and shows that it resulted from selective evolutionary forces. source
- Not checked yetcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § SARS-CoV-2 evolution · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The increasing number of SArS-cov-2 variants share a repertoire of mutations that is enabling the virus to spread despite rising population immunity while maintaining or increasing its replication fitness.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
In the paper
“In a post-hoc analysis of a NVX-CoV2373 clinical trial, vaccine efficacy was 86.3% against Alpha variants compared with 96.4% against non-Alpha variants 212 (TABLe 2).”
What the sources say
- Not checked yetcites [212] Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107659 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“By the second quarter of 2021, the Alpha variant accounted for the majority of infections in the USA and many European countries 23,196 .”
What the sources say
- Not checked yetcites [23] Hodcroft, E. CoVariants: SARS-CoV-2 mutations and variants of interest (NextStrain). CoVariants https://covariants.org/ (2021).
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“It was also associated with threefold to eightfold higher upper-airway levels [199][200][201]”
What the sources say
- Not checked yetcites [199] Golubchik, T. et al. Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. Preprint at bioRxiv https://doi.org/10.1101/2021.01.12.20249080 (2021). source
- Not checked yetcites [200] Kidd, M. et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J. Infect. Dis. 223, 1666–1670 (2021). source
- Not checked yetcites [201] Borges, V. et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Eur. Surveill. 26, 2100131 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 8
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“E484K has resulted in 3-fold to 10-fold reduced susceptibility to about 30% and >10-fold reduced susceptibility to about 10% of convalescent plasma samples”
What the sources say
- Partly supportedcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. sourceExperimental — accuracy not yet measured
The Discussion’s E484K row in Fig. 3b reports more than 10-fold reduced neutralization for 2 of 20 convalescent plasma samples (10%), as claimed. But 12 of 20 samples (60%), not about 30%, show reductions between 3-fold and 10-fold. (LLM, conf=0.88)
- Partly supportedcites [130] Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57.e9 (2021). sourceExperimental — accuracy not yet measured
The Results section, “Functional and Evolutionary Constraint on Antibody-Escape Mutations” (page unavailable), says mutations at site 484 have been reported to escape polyclonal sera. It does not give the claimed 3- to 10-fold or >10-fold reductions, the percentages of convalescent plasma samples, or those findings specifically for E484K. (LLM, conf=0.82)
- Not checked yetcites [160] Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488.e4 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
What the sources say
- Partly supportedcites [99] Faulkner, N. et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. Elife 10, e69317 (2021). sourceExperimental — accuracy not yet measured
The Results and Discussion report reduced neutralisation of B.1.351 (Beta) by B.1.1.7 (Alpha) sera, with a 7.7-fold change and a range of 3.4- to 17.9-fold. They do not report the claimed breakdown of 59% and 18%; the Materials and methods describe 29 patients with B.1.1.7 infection, not 34. (LLM, conf=0.88)
- Partly supportedcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). sourceExperimental — accuracy not yet measured
The Results section reports reduced neutralization of Beta (B.1.351), but the 34 convalescent samples were collected before Alpha (B.1.1.7) emerged. The paper reports a separate Alpha-infected group of 13 patients, not 34, and does not report the claimed 59% and 18% breakdown for that group. Page numbers are unavailable in our copy. (LLM, conf=0.86)
- Partly supportedcites [221] McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science 373, 648–654 (2021). sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports reduced neutralization of the Beta variant (B.1.351) by convalescent plasma. But its nine donors were likely infected with Wuhan-1 or a related virus, not Alpha, and it does not report the claimed 34 samples or the 59% and 18% breakdowns. (LLM, conf=0.84)
plaindirectn = 34- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By June 2021, the Gamma variant accounted for a high proportion of infections in several South American and Caribbean countries 196 and 10% of US infections 33 .”
What the sources say
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
- Partly supportedcites [33] Bolze, A. et al. Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States. Preprint at medRxiv https://doi.org/10.1101/2021.06.20.21259195 (2021). sourceExperimental — accuracy not yet measured
The Results (page not available) report that Gamma reached 15% of sequenced US samples by May 28–June 3, 2021. This supports a substantial US presence around June, but not the cited figure of 10% of infections. The South American and Caribbean statement carries a different citation and is not assessed here. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
What the sources say
- Supportedcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [29] Buss, L. F. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371, 288–292 (2021). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [30] Sabino, E. C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 397, 452–455 (2021). source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the mRNA vaccines appear to often elicit memory B cells that undergo somatic hypermutation, which should broaden the response to viruses with variant spike proteins 239,240 .”
What the sources say
- Partly supportedcites [239] Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021). sourceExperimental — accuracy not yet measured
The Memory B cells section reports continued somatic hypermutation after infection, and the Discussion says mRNA vaccination enhances memory B-cell responses and likely protects vaccinated convalescent individuals against variants (page not specified). But the paper says vaccine-driven expansion of persistent memory clones does not accumulate large numbers of additional mutations. It does not establish that mRNA vaccines often elicit this mutation-driven broadening in people without prior infection. (LLM, conf=0.88)
- Partly supportedcites [240] Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature https://doi.org/10.1038/s41586-021-03738-2 (2021). sourceExperimental — accuracy not yet measured
The paper reports persistent germinal-centre responses after mRNA vaccination and finds that a small fraction of cross-reactive B-cell clones had higher somatic hypermutation, suggesting a pre-existing memory B-cell origin (Abstract; page not provided). It does not show that vaccination often elicits memory B cells that undergo new somatic hypermutation, or establish that this process broadens responses to variant SARS-CoV-2 spike proteins. (LLM, conf=0.85)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of convalescent plasma samples, about 40% had 3-fold to 10-fold and 15% had >10-fold reduced neutralizing activity 100,122,234 .”
What the sources say
- Partly supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). sourceExperimental — accuracy not yet measured
The Results section, ‘Neutralization of B.1.617.1 by convalescent serum’ (page unavailable), reports reduced neutralization of the Kappa variant in convalescent samples, including a 3.9-fold reduction in geometric mean titer for B.1.617.1-B. It does not report that about 40% of samples had 3- to 10-fold reductions or that 15% had reductions greater than 10-fold; a group mean cannot establish those sample-level proportions. (LLM, conf=0.84)
- Partly supportedcites [122] Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med. 385, 664–666 (2021) sourceExperimental — accuracy not yet measured
The paper’s main text (page unavailable) reports reduced neutralizing activity against B.1.617.1 (Kappa) in convalescent serum, including a lower geometric mean titer than against WA1/2020. It does not report that about 40% of samples had a 3- to 10-fold reduction or that 15% had a greater-than-10-fold reduction. (LLM, conf=0.86)
- Partly supportedcites [234] Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 36, 109415 (2021). sourceExperimental — accuracy not yet measured
The Results section ('Diminished neutralization by plasma from COVID-19 convalescent patients'; page unavailable) reports reduced neutralization of B.1.617 by plasma from 15 patients, averaging about 2-fold. It does not report that about 40% of samples had 3- to 10-fold reductions or that 15% had reductions greater than 10-fold. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The levels of neutralizing mAbs elicited by the mRNA vaccines has been high and in most persons are likely to be maintained for many months above the levels required for protection against even the most resistant circulating variants 164,239,240 .”
What the sources say
- Partly supportedcites [164] Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl Med. 13, eabi9915 (2021). sourceExperimental — accuracy not yet measured
The Results report high neutralizing-antibody titers in mRNA-1273 vaccine sera collected up to 90 days after the second dose, and the Introduction reports that these sera retained substantial neutralization despite mutations to major RBD epitopes. The paper studies serum antibody responses, not levels of monoclonal antibodies (mAbs), and does not establish that most people will remain above a protective threshold for many months against the most resistant circulating variants. Page numbers are unavailable in our copy. (LLM, conf=0.86)
- Partly supportedcites [239] Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021). sourceExperimental — accuracy not yet measured
The Plasma SARS-CoV-2 antibody reactivity section reports high neutralizing titres against circulating variants after mRNA vaccination, but its vaccinated participants had previously recovered from infection. The Discussion describes sustained neutralizing activity after infection, not maintenance for many months after vaccination; the paper does not establish a protective threshold or show that most vaccine recipients remain above it. (LLM, conf=0.88)
- Partly supportedcites [240] Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature https://doi.org/10.1038/s41586-021-03738-2 (2021). sourceExperimental — accuracy not yet measured
The paper’s neutralization-results passage (labelled Abstract in our copy; page unavailable) reports increased serum neutralizing titres after BNT162b2 vaccination, including against B.1.1.7 and B.1.351. Its concluding passage reports germinal-centre responses lasting at least 12 weeks, but does not establish that neutralizing monoclonal-antibody levels in most people remain above a protective threshold for many months, including against the most resistant circulating variants. (LLM, conf=0.88)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The Alpha variant is susceptible to neutralization by most neutralizing mAbs as well as by most plasma samples from previously infected persons 97,102,121,149,159,[203][204][205][206] (fIg.5).”
What the sources say
- Not checked yetcites [97] Chen, X. et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab646 (2021). This paper presents a systematic review and meta-analysis of in vitro neutralization studies of SARS-CoV-2 variants by convalescent and vaccinee plasma. source
- Not checked yetcites [102] Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211 (2021). source
- Not checked yetcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The fact that the Alpha variant is rarely associated with reduced susceptibility to convalescent plasma is consistent with it not being associated with an increased risk of reinfection 207 .”
What the sources say
- Not checked yetcites [207] Graham, M. S. et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 6, e335–e345 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“associated with increased transmissibility, increased risk of reinfection and/or reduced vaccine efficacy”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Beta variant is associated with reduced susceptibility to many mAbs because E484K interferes with binding of several RBM class 1 and 2 mAbs and K417N interferes with the binding of several RBM class 1 mAbs 104,117,121,163,217 .”
What the sources say
- Not checked yetcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). source
- Not checked yetcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). source
- Not checked yetcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Alpha variant also contains several non-spike mutations including nsp6:Δ106-108 and the nucleocapsid mutations D3L, R203K and G204R, which may increase transmission by antagonizing innate immunity 25,[185][186][187] .”
What the sources say
- Not checked yetcites [25] Martin, D. P. et al. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape. Preprint at medRxiv https://doi.org/10.1101/2021.02.23.21252268 (2021). source
- Not checked yetcites [185] Thorne, L. G. et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. Preprint at bioRxiv https://doi.org/10.1101/2021.06.06.446826 (2021). This systems biology study shows that in contrast to earlier SARS-CoV-2 variants, the alpha variant may owe its increased transmissibility and virulence to its antagonism of cellular innate immunity. source
- Not checked yetcites [186] Jiang, H. et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol. Immunol. 17, 998–1000 (2020). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“N501Y increases ACE2 affinity 128,146,147 and increases virus replication in human upper-airway cells and in the upper respiratory tracts of hamsters 127”
What the sources say
- Not checked yetcites [128] Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020). source
- Not checked yetcites [146] Zhu, X. et al. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol. 19, e3001237 (2021).
- Not checked yetcites [127] Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Preprint at bioRxiv https://doi.org/10.1101/2021.03.08.434499 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
What the sources say
- Not checked yetcites [211] Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 385, 187-189 (2021). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Even though E484Q is more likely than T478K to evade antibody neutralization 48,100,165 , only the Delta variant has demonstrated increased transmissibility, spreading to 54 countries and rapidly replacing the Alpha variant in the UK 32,35 and the USA 33 .”
What the sources say
- Not checked yetcites [48] Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020). source
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [165] Ferreira, I. et al. SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab368 (2021). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It also contains five NTD mutations, of which L18F has been shown to interfere with the binding of NTD-targeting neutralizing antibodies 51 .”
What the sources say
- Not checked yetcites [51] McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347.e16 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It was estimated to result in virus levels 3-4 times higher than earlier variants and to be responsible for an estimated 1.1-fold to 1.8-fold higher mortality 19 .”
What the sources say
- Not checked yetcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of the five FDA EUA-approved mAbs, bamlanivimab, etesevimab and casirivimab are largely inactive against B.1.351whereas imdevimab and sotrovimab, which bind to the RBD core, retain neutralizing activity 104,109,117,175,204 (TABLe 1).”
What the sources say
- Not checked yetcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). source
- Not checked yetcites [109] Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 3949–3961 (2021). source
- Not checked yetcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of convalescent plasma samples, about 40% display 3-fold to 10-fold and 10% display >10-fold reduced Iota variant neutralizing activity 166,235 .”
What the sources say
- Not checked yetcites [166] Zhang, L. et al. Comparison of 10 emerging SARS-CoV-2 variants: infectivity, animal tropism, and antibody neutralization. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-492659/v1 (2021). source
- Not checked yetcites [235] Zhou, H. et al. B.1.526 SARS-CoV-2 variants identified in new york city are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. mBio https://doi.org/10.1128/mBio.01386-21 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although SARS-CoV-2 variants differ in their transmission rates, disease severity and risk of reinfection, there is no evidence that they are differentially affected by non-pharmaceutical public health measures such as social distancing and the use of personal protective equipment, or that they will respond differently to most antiviral therapies.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Zeta variant was common in Brazil in late 2020 and early 2021 (ref. 157 ), but appears to be decreasing in prevalence.”
What the sources say
- Not checked yetcites [157] Ferrareze, P. A. G. et al. E484K as an innovative phylogenetic event for viral evolution: genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. Infect. Genet. Evol. 93, 104941 (2021). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The two most recently approved mAb preparations, casirivimab/imdevimab and sotrovimab, retain activity against all VOCs and VOIs, in part because imdevimab and sotrovimab target the RBD core whereas the most prevalent immune escape mutations are in the RBD RBM.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Theta variant was first reported in March 2021 in the Philippines.It contains 13 lineage-defining mutations including N501Y, E484K, P681H and the NTD deletion at positions 141-143 (refs 155,156 ).”
What the sources say
- Not checked yetcites [155] Bascos, N. A. D., Mirano-Bascos, D. & Saloma, C. P. Structural analysis of spike protein mutations in an emergent SARS-CoV-2 variant from the Philippines. Preprint at bioRxiv https://doi.org/10.1101/2021.03.06.434059 (2021). source
- Not checked yetcites [156] Tablizo, F. A. et al. Genome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein mutations detected from the Central Visayas Region of the Philippines. Preprint at bioRxiv https://doi.org/10.1101/2021.03.03.21252812 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of plasma samples from recipients of an mRNA vaccine, approximately 55% had 3-fold to 10-fold and 5% had >10-fold reduced neutralizing activity 100,118,122,234 .”
What the sources say
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [118] Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). source
- Not checked yetcites [122] Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med. 385, 664–666 (2021) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Iota variant was first identified in New York state.In June 2021, it had a prevalence of 5-10% in the USA but remained rare outside the USA 154 .”
What the sources say
- Not checked yetcites [154] Annavajhala, M. K. et al. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. Preprint at bioRxiv https://doi.org/10.1101/2021.02.23.21252259 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Beta and Gamma variants are each associated with increased transmissibility because of their ability to evade humoral immunity and cause reinfections.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“AY.1 and AY.2 are recently reported sub-lineages of the Delta variant that have developed additional mutations including the RBD mutation K417N (ref. 196 ).”
What the sources say
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“It is highly prevalent in several South American countries and is associated with reduced susceptibility to the locally used CoronaVac vaccine 238 .”
What the sources say
- Not checked yetcites [238] Acevedo, M. L. et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. Preprint at medRxiv https://doi.org/10.1101/2021.06.28.21259673 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In case-control studies from the UK, the BNT162b vaccine was approximately 85% effective for the Delta variant whereas the AZD1222 vaccine was approximately 60% effective 232,233 .”
What the sources say
- Not checked yetcites [232] Bernal, J. L. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. N. Engl. J. Med. 385, 585–594 (2021). source
- Not checked yetcites [233] Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It was estimated to be about 20% more transmissible than co-circulating lineages and to be associated with twofold higher upper-airway virus levels 123,192 .”
What the sources say
- Not checked yetcites [123] Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437.e8 (2021). source
- Not checked yetcites [192] Peng, J. et al. Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab283 (2021). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Eta variant is present at low levels in many countries, with Nigeria having the highest proportion of infections 236 .”
What the sources say
- Not checked yetcites [236] Ozer, E. A. et al. High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.525 lineage in Oyo State, Nigeria. Preprint at medRxiv https://doi.org/10.1101/2021.04.09.21255206 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It results in approximately 3-fold to 10-fold reduced susceptibility to 45% and >10-fold reduced susceptibility to 5% of convalescent plasma samples 100,118,214,215,231 (fIg.5).”
What the sources say
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [118] Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). source
- Not checked yetcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Alpha and Delta variants are each associated with increased transmissibility and greater disease severity because of immune evasion, and potentially because of higher virus levels resulting from the antagonism of innate immunity.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“This paper presents a meta-analysis showing that the level of neutralizing antibodies elicited by a vaccine is strongly correlated with its efficacy.”
What the sources say
- Not checked yetcites Khoury, D. S. et al.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This post-hoc analysis of a clinical trial shows that the beta variant was frequently responsible for reinfections in South Africa.”
What the sources say
- Not checked yetcites Shinde, V. et al.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This study demonstrates the likely importance of SARS-CoV-2 neutralizing mAb Fc-effector functions in an animal model.”
What the sources say
- Not checked yetcites Schäfer, A. et al.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This post-hoc analysis of a clinical trial shows that AZD1222 appeared ineffective at preventing infection with the beta variant.”
What the sources say
- Not checked yetcites Madhi, S. A. et al.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This experimental study shows that the plasma from persons infected with the beta variant can usually neutralize pre-variant viruses.”
What the sources say
- Not checked yetcites Moyo-Gwete, T. et al.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This systems biology study shows that in contrast to earlier SARS-CoV-2 variants, the alpha variant may owe its increased transmissibility and virulence to its antagonism of cellular innate immunity.”
What the sources say
- Not checked yetcites Thorne, L. G. et al.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This paper demonstrates that a high proportion of neutralizing antibodies elicited by SARS-CoV-2 infection will bind poorly to epitopes containing the spike RBD mutation E484K.”
What the sources say
- Not checked yetcites Greaney, A. J. et al.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These VOCs exhibit increased transmissibility and/or immune evasion, traits that have been linked to mutations in the viral spike (S) protein”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Tao et al., 2021
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Self-citation
Research works printed but not linked: 1
- Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA 325, 1896–1898 (2021). · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 870
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2095305 · Cited by 18
“After the surge of the new variants, RBDs with the corresponding mutated sequences started to be investigated both theoretically and experimentally (Abdool Karim & de Oliveira, 2021; Davies et al., 2021; Hoffmann, Arora, et al., 2021; Starr et al., 2020; Tao et al., 2021; Toyoshima et al., 2020).”
BackgroundDhamotharan, K., Korn, S. M., Wacker, A., Becker, M. A., Günther, S., Schwalbe, H., & Schlundt, A. (2024) · Nature Communications · doi:10.1038/s41467-024-55024-0 · Cited by 11
Singh, O. N., Berry, U., Joshi, G., Asuru, T. R., Chandrasekar, K., Narayanan, S., Srivastava, P., Tiwari, M., Chattopadhyay, S., Mehdi, F., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113498 · Cited by 13
“23,24 Omicron B.1.1.529 ( BA.1) became the most dominant circulating strain with 22 subvariants accounting for 87% of infections.”
InfluentialDual structure-switching aptamer-mediated signal amplification cascade for SARS-CoV-2 detection.
Lim, J.-W., Son, S. U., Ki, J., Kim, S., Lee, J.-N., Jang, S., Seo, S., Jang, H., Kang, T., Jung, J., et al. (2024) · Biosensors & bioelectronics · doi:10.1016/j.bios.2024.116375 · Cited by 11
Acar, D. D., Witkowski, W., Wejda, M., Wei, R., Desmet, T., Schepens, B., Cae, S. D., Sedeyn, K., Eeckhaut, H., Fijałkowska, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104960 · Cited by 12
Clinical development of antivirals against SARS-CoV-2 and its variants
Lan, Q., Yan, Y., Zhang, G., Xia, S., Zhou, J., Lu, L., & Jiang, S. (2023) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2023.100208 · Cited by 9
“…variants of concern (VOCs) with increased infectivity and transmissibility, as well as resistance to antibody neutralization from vaccine-elicited sera and convalescent plasma, has become a major obstacle against ending the COVID-19 epidemic (Wang et al., 2021b; Tao et al., 2021; Su et al., 2022).”
BackgroundKing, E., Garrett, H. E., Abernathy, H., Cassidy, C. A., Cabell, C. R., Shook‐Sa, B. E., Juliano, J. J., Boyce, R. M., Aiello, A. E., & Ciccone, E. J. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113523 · Cited by 15
“However, household phlebotomy visits pose a risk of COVID-19 transmission between participants and staff, especially as new variants that are more transmissible become more prevalent (1).”
BackgroundVariation in synonymous evolutionary rates in the SARS-CoV-2 genome
Sun, Q., Zeng, J., Tang, K. L., Long, H., Zhang, C., Zhang, J., Tang, J. Y., Xin, Y., Zheng, J., Sun, L., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1136386 · Cited by 11
“For better monitoring and research (Tao et al., 2021; Kumar et al., 2022), the World Health Organization has listed some of the key viral variants or lineages with importantmutations as variants of concern.”
BackgroundGuzzi, P., Paola, L. D., Puccio, B., Lomoio, U., Giuliani, A., & Veltri, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-30052-w · Cited by 11
“For instance, the mutations of the Delta variants on S protein have shown a reduction in the reaction to antibodies 38 .”
BackgroundCantoni, D. M., Siracusano, G., Neto, M. M., Pastori, C., Fantoni, T., Lytras, S., Genova, C. D., Hughes, J., on behalf of the Ambulatorio Medico San Luca Villanuova Group, Lopalco, L., et al. (2022) · Vaccines · doi:10.3390/vaccines11010058 · Cited by 13
“Moreover, successful generation of various vaccine platforms have been used to protect individuals from infection and severe disease [26], though their effectiveness is diminished as newer and more immune evasive variants arise [27].”
BackgroundOn the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses
Warger, J., & Gaudieri, S. (2022) · Viruses · doi:10.3390/v15010070 · Cited by 11
Kimbrel, J. A., Moon, J. Y., Avila-Herrera, A., Martí, J. M., Thissen, J. B., Mulakken, N., Sandholtz, S. H., Ferrell, T., Daum, C. G., Hall, S., et al. (2022) · Viruses · doi:10.3390/v14122775 · Cited by 11
Wang, R.-Y., Zhai, G., Zhu, G., Wang, M., Gong, X., Zhang, W.-D., Ge, G.-B., Chen, H., & Chen, L. (2022) · Bioorganic chemistry (Print) · doi:10.1016/j.bioorg.2022.106264 · Cited by 11
Kwon, H., Košíková, M., Tang, W., Ortega‐Rodriguez, U., Radvák, P., Xiang, R., Mercer, K. E., Muskhelishvili, L., Davis, K., Ward, J. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105507 · Cited by 11
“The World Health Organization (WHO) has classified emerging variants that cause global transmission and severe disease with enhanced resistance to neutralizing antibodies as a variant of concern (VOC), e.g. Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and the latest Omicron (B.1.1.529); while other…”
InfluentialBoorla, V. S., Chowdhury, R., Ramasubramanian, R., Ameglio, B., Frick, R., Gray, J. J., & Maranas, C. D. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26422 · Cited by 18
“The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a threat due to the continued emergence of variants.(1,2) Early on in the pandemic, convalescent Veda Sheersh Boorla, Ratul Chowdhury, Ranjani Ramasubramanian, and Brandon Ameglio contributed equally to this st…”
BackgroundAssociation of mortality and early tracheostomy in patients with COVID-19: a retrospective analysis
Flinspach, A., Booke, H., Zacharowski, K., Balaban, Ü., Herrmann, E., & Adam, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-19567-w · Cited by 11
Rodrigues, D., Nastri, A. C. D. S. S., Magri, M. M., de Oliveira, M. S., Sabino, E., Figueiredo, P. H. M. F., Levin, A., Freire, M., Harima, L., Nunes, F. L. S., et al. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-01931-5 · Cited by 11
Agudelo, M., Muecksch, F., Schaefer-Babajew, D. J., Cho, A., DaSilva, J., Bednarski, E., Ramos, V., Oliveira, T. Y., Cipolla, M., Gazumyan, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220367 · Cited by 9
“Gamma differs from Beta at 13 positions including 417T/N in the RBD (Faria et al., 2021; Tegally et al., 2021).”
BackgroundPouremamali, A., Babaei, A., Malekshahi, S., Abbasi, A., & Rafiee, N. (2022) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-022-00314-9 · Cited by 11
Junker, D., Becker, M., Wagner, T. R., Kaiser, P. D., Maier, S. M., Grimm, T. M., Griesbaum, J., Marsall, P., Gruber, J., Traenkle, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac498 · Cited by 17
SARS2Mutant: SARS-CoV-2 amino-acid mutation atlas database
Rahimian, K., Mahmanzar, M., Mahdavi, B., Arefian, E., Kuehu, D., & Deng, Y.-P. (2022) · bioRxiv · doi:10.1101/2022.06.12.495856 · Cited by 11
“One of the notable reasons concerning the emergence of new variants is the probability of reinfecting individuals or those fully vaccinated (vaccine breakthrough) [12].”
BackgroundAdenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein
Khan, M. S., Kim, E. Y., McPherson, A. C., Weisel, F. J., Huang, S., Kenniston, T. W., Percivalle, E., Cassaniti, I., Baldanti, F., Meisel, M., et al. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac015 · Cited by 13
“Global vaccine inequality has, and will continue to, lead to new SARS-CoV-2 variants that may be able to escape natural and vaccine acquired immunity [18-21].”
BackgroundSARS-CoV-2 Infection and Possible Neonatal Neurological Outcomes: A Literature Review
de Moraes, F. M., de Souza, J. W. P. S., Alves, L. P., de Siqueira, M. F. R., dos Santos, A. P. A., Berardo, M. M. D. C., Granja, M. G., & Castro-Faria-Neto, H. C. (2022) · Viruses · doi:10.3390/v14051037 · Cited by 12
“The SARS-CoV-2 VOCs and VOIs circulating at present carry various mutations, most of which are in the spike gene [90].”
BackgroundMutation T9I in Envelope confers autophagy resistance to SARS-CoV-2 Omicron
Klute, S., Nchioua, R., Cordsmeier, A., Vishwakarma, J., Koepke, L., Alshammary, H., Jung, C., Hirschenberger, M., Hoenigsperger, H., Fischer, J.-R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112974 · Cited by 9
Kim, G., Elnaggar, J., Varnado, M., Feehan, A. K., Tauzier, D., Rose, R., Lamers, S. L., Sevalia, M., Nicholas, N., Gravois, E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1357731 · Cited by 10
Chakraborty, C., Mallick, B., Bhattacharya, M., & Byrareddy, S. N. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2023.100347 · Cited by 10
Shared sequence characteristics identified in non-canonical rearrangements of HSV-1 genomes
Shitrit, A., Nisnevich, V., Rozenshtein, N., Kobo, H., Phan, H. V., Tay, S., Szpara, M. L., Weitzman, M. D., Drayman, N., & Kobiler, O. (2023) · Journal of Virology · doi:10.1128/jvi.00955-23 · Cited by 10
Association between SUMF1 polymorphisms and COVID-19 severity
Liang, S.-H., Gao, H.-X., He, T.-X., Li, L., Zhang, X., Zhao, L., Chen, J., Xie, Y.-Y., Bao, J., Gao, Y., et al. (2023) · BMC Genomic Data · doi:10.1186/s12863-023-01133-6 · Cited by 10
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
Kegler, A., Drewitz, L., Arndt, C., Daglar, C., Loureiro, L. R., Mitwasi, N., Neuber, C., Soto, K. E. G., Bartsch, T., Baraban, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204543 · Cited by 11
“As SARS-CoV-2 is a rapidly evolving virus with the fast emergence and spread of various sublineages (52, 53), the high occurrence of novel mutations represents a major challenge for the development of vaccines and mAb therapies (2, 3, 54–56).”
BackgroundMonteiro, H., Neto, A., Kahn, R., Santos, G. S., Carmona, H. A., de Andrade, J. S. D., & Castro, M. (2023) · medRxiv · doi:10.1101/2023.06.06.23291015 · Cited by 10
Computational optimization of delivery parameters to guide the development of targeted Nasal spray
Du, J., Shao, X., Bouteiller, J.-M. C., Lu, A., Asante, I., Louie, S., Humayun, M., & Lazzi, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-30252-4 · Cited by 10
“to mimic the liquid property of viral particles; (2) liquid particles with a dynamic viscosity of 2mPa*s to mimic the property of sprayed particles.”
BackgroundSuleman, M., Luqman, M., Wei, D., Ali, S., Ali, S. S., Khan, A., Khan, H., Ali, Z., Khan, W., Rizwan, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15083 · Cited by 13
“The variant of interest was kappa, theta, eta, zeta, lota, and epsilon [15].”
Song, Y., Liu, S., Lee, H.-J., Liao, H., Liu, C.-T., Wu, M., & Yen, H. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.03.008 · Cited by 14
“529 (Omicron) variants.(2) However, the Omicron variant is the most mutated SARS-CoV-2 variant with high transmissibility and immune evasion.”
Haddad-Boubaker, S., Arbi, M., Souiai, O., Chouikha, A., Fares, W., Edington, K., Sims, S., Cammà, C., Lorusso, A., Diagne, M., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.990832 · Cited by 10
“First detected on March 01 2021, it spread rapidly to almost all countries of the world, replacing the Alpha variant which was predominating globally (7, 11).”
BackgroundTrivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice
Khan, M. S., Kim, E. S., Huang, S., Kenniston, T. W., & Gambotto, A. A. (2023) · Vaccines · doi:10.3390/vaccines11020314 · Cited by 11
Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
Giotis, E. S., Cil, E., & Brooke, G. N. (2022) · Viruses · doi:10.3390/v14122728 · Cited by 8
Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air TravelPreprint
Tegally, H., Wilkinson, E., Martin, D. P., Moir, M., Brito, A. F., Giovanetti, M., Khan, K., Huber, C., Bogoch, I. I., San, J. E., et al. (2022) · medRxiv · doi:10.1101/2022.11.22.22282629 · Cited by 13
“Along with some less successful novel lineages (termed variants of interest or VOIs), these VOCs were characterized by a combination of increased intrinsic transmissibility, sometimes enhanced immune evasion capabilities, and increased pathogenicity 4 .”
Zareei, S., Pourmand, S., & Amanlou, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.996005 · Cited by 10
Wu, T. T., Zhu, Y., Liu, N., Hu, Y., Chong, H., & He, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1022006 · Cited by 11
“By generating a group of mutant viruses carrying single or combination mutations, we verified that K417N and N501Y substitutions in RBD critically determined the high resistance phenotype of VOCs.”
BackgroundInfluentialAntibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
Błaszczuk, A., Michalski, A., Sikora, D., Malm, M., Drop, B., & Polz‐Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10101728 · Cited by 9
“, was first discovered in India and soon was detected all over the world, displacing previous strains [7].”
BackgroundSharma, P., Kumar, M., Tripathi, M. K., Gupta, D., Vishwakarma, P., Das, U., & Kaur, P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106129 · Cited by 14
“The causative agent, SARS-CoV-2, is continuously evolving into novel variants, which makes the management of COVID-19 extremely challenging [10,11].”
Lu, Y., Zhang, B., Wang, N., Li, M., & Xi, N. (2022) · Crystals · doi:10.3390/cryst12070990 · Cited by 10
Sarker, H., Panigrahi, R., Hardy, E., Glover, J. N. M., Elahi, S., & Fernandez-Patron, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906687 · Cited by 10
“Since its detection in Wuhan in December 2019, SARS-CoV2 has mutated giving rise to variants of concern (such as the Alpha, Beta, Gamma, Delta and Omicron) that have numerous mutations in the RBD of spike protein SARS-CoV-2 S1 (41, 49).”
BackgroundFaster SARS-CoV-2 sequence validation and annotation for GenBank using VADR
Nawrocki, E. P. (2022) · bioRxiv · doi:10.1101/2022.04.25.489427 · Cited by 10
Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., et al. (2022) · Viruses · doi:10.3390/v14050854 · Cited by 11
“However, since the outbreak of the epidemic, genetic variants of SARS-CoV-2 have been emerging and circulating around the world [3].”
BackgroundInfluentialMolecular epidemiological features of SARS-CoV-2 in Japan, 2020–1
Ode, H., Nakata, Y., Nagashima, M., Hayashi, M., Yamazaki, T., Asakura, H., Suzuki, J., Kubota, M., Matsuoka, K., Matsuda, M., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac034 · Cited by 18
der Moeren, N. V., Selhorst, P., Ha, M. K., Heireman, L., Gaal, P.-J. V., Breems, D. A., Meysman, P., Laukens, K., Verstrepen, W. A., Gasse, N. V., et al. (2022) · Viruses · doi:10.3390/v14040752 · Cited by 10
“Interestingly ∆143 and ∆144 are signature mutations in VOC alpha, and variants of interest (VOI) eta, theta, and iota, while ∆242 and ∆243 developed in VOC beta and ∆243 in VOI theta [15,16].”
BackgroundGaiarsa, S., Giardina, F., Biffignandi, G. B., Ferrari, G., Piazza, A., Tallarita, M., Novazzi, F., Bandi, C., Paolucci, S., Rovida, F., et al. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198786 · Cited by 12
Padilha, D. A., Filho, V. B., Moreira, R. S., Soratto, T. A. T., Maia, G. A., Christoff, A. P., Barazzetti, F. H., Schörner, M. A., Ferrari, F. L., Martins, C. L., et al. (2022) · Viruses · doi:10.3390/v14040695 · Cited by 14
“Some new variants have distinctive biological characteristics from their predecessors, such as better transmission, immunological escape or distinguishing clinical symptoms [6].”
BackgroundRapid SARS-CoV-2 Intra-Host and Within-Household Emergence of Novel Haplotypes
Manuto, L., Grazioli, M., Spitaleri, A., Fontana, P., Bianco, L., Bertolotti, L., Bado, M., Mazzotti, G., Bianca, F., Onelia, F., et al. (2022) · Viruses · doi:10.3390/v14020399 · Cited by 10
“Examples of viral evolution are the different variants of concern that emerged since the beginning of the pandemic, such as the Alpha variant (originally identified in the UK), the Beta variant (originally identified in South Africa), the Gamma variant (originally identified in Brazil), the Delta variant (originally i…”
BackgroundTolksdorf, B., Heinze, J., Niemeyer, D., Röhrs, V., Berg, J., Drosten, C., & Kurreck, J. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105879 · Cited by 9
Coria, L. M., Rodriguez, J. M., Demaría, A., Bruno, L. A., Medrano, M. R., Castro, C. P., Castro, E. F., Priore, S. A. D., Hernando-Insúa, A., Kaufmann, I. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45180-8 · Cited by 11
Li, Y., Chen, J., Wei, J., Liu, X., Lu, Y., Yu, L., Ding, D., & Yang, Y. P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01981-5 · Cited by 12
Antiviral activity of the human endogenous retrovirus‐R envelope protein against SARS‐CoV‐2
Ansari, S., Gupta, N., Verma, R., Singh, O. N., Gupta, J., Kumar, A., Yadav, M. K., Binayke, A., Tiwari, M., Periwal, N., et al. (2023) · EMBO Reports · doi:10.15252/embr.202255900 · Cited by 10
“Some of them, such as the delta and the omicron variants, are serious public health concerns (Tao et al , 2021; Skarbinski et al , 2022).”
A tissue specific-infection mouse model of SARS-CoV-2
Yang, B. Y., Liu, C., Ju, X., Wu, B., Wang, Z., Dong, F., Yu, Y., Hou, X., Fang, M., Gao, F., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00536-0 · Cited by 10
The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant
Pegg, C. L., Modhiran, N., Parry, R. H., Liang, B., Amarilla, A. A., Khromykh, A. A., Burr, L. D., Young, P. R., Chappell, K. J., Schulz, B. L., et al. (2023) · Glycobiology · doi:10.1093/glycob/cwad097 · Cited by 13
“…defined epitope-specific monoclonal antibodies (mAbs) including anti-RBD (B38, CB6, CR3022, 2M10B11 and S309) and anti-NTD (4A8, COVA2-17 and COVA1-22) bound differently to Wu-1 and Gamma spike proteins, consistent with previous studies (Caniels et al. 2021; Tao et al. 2021; Wang et al. 2021b).”
Silva, J. P., de Lima, A. D., Alvim, L., Malta, F., Mendonça, C. P., de Carvalho, A. H. B., Rios, J. S. H., Fonseca, P., Queiroz, D. C., Santos, L. C. G. D. A. E., et al. (2023) · Viruses · doi:10.3390/v15041017 · Cited by 9
“The VOC’s establishment has also been responsible for upsurges in cases and deaths in Brazil [18], for example, the collapse of the health system observed in Manaus in early 2021 by Gamma VOC [14,19], the increase in the number of severe cases due to Delta VOC in mid-2021 [20], and finally, the rise in the number of c…”
BackgroundYamasaki, H., Imai, H., Tanaka, A., & Otaki, J. M. (2023) · Microorganisms · doi:10.3390/microorganisms11020397 · Cited by 8
“002 mutations per nucleotide per year [8].”
Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant
Jeican, I. I., Inișca, P., Gheban, D., Anton, V., Lazăr, M., Vică, M., Mironescu, D., Rebeleanu, C., Crivii, C., Aluaș, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020279 · Cited by 9
A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2
Chaube, U., Patel, B., & Bhatt, H. (2022) · 3 Biotech · doi:10.1007/s13205-022-03430-w · Cited by 12
Matthews, A. M., Biel, T., Ortega-Rodriguez, U., Falkowski, V. M., Bush, X., Faison, T., Xie, H., Agarabi, C., Rao, V. A., & Ju, T.-Z. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278294 · Cited by 9
“However, multiple SARS-CoV-2 Variants of Concern (VoC) have emerged with enhanced transmissibility and resistance to existing humoral immunity, and/or increased disease severity, resulting in reduced efficacy or even failure of some countermeasures [5].”
BackgroundKwan, B. M., Sobczak, C., Gorman, C., Roberts, S. C., Owen, V., Wynia, M., Ginde, A., Pena-Jackson, G., Ziegler, O., & DeCamp, L. R. (2022) · medRxiv · doi:10.1371/journal.pone.0274043 · Cited by 9
“The first mAb for COVID-19 (bamlanivimab) was authorized for emergency use in the United States in November 2020 to treat symptomatic COVID-19 among high-risk outpatient populations [1-3].”
Zhang, H., Gong, X., Peng, Y., Saravanan, K. M., Bian, H., Zhang, J. Z. H., Wei, Y., Pan, Y. F., & Yang, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.933102 · Cited by 9
Antigenic escape is accelerated by the presence of immunocompromised hosts
Kumata, R., & Sasaki, A. (2022) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2022.1437 · Cited by 8
“The ongoing epidemic of SARS-CoV-2 has been accompanied by the emergence of several variants, and attention has focused on the evolutionary causes of such variants [2,3].”
BackgroundInfluentialCortés-Sarabia, K., Gutiérrez-Torres, M., Mendoza-Renteria, E. M., Leyva‐Vázquez, M. A., Vences-Velázquez, A., Hernández‐Sotelo, D., Beltrán‐Anaya, F. O., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2022) · Vaccines · doi:10.3390/vaccines10060909 · Cited by 12
SARS-CoV-2 Omicron subvariants evolved to promote further escape from MHC-I recognitionPreprint
Moriyama, M., Lucas, C., Monteiro, V., & Iwasaki, A. (2022) · bioRxiv · doi:10.1101/2022.05.04.490614 · Cited by 9
“*, p<0.05; **, p< 0.01; ***, p< 0.001 Variant-specific mutations are found in the ORF8 gene of SARS-CoV-2 Because previous studies revealed the association between 382 nt deletion spanning ORF7b-ORF8 gene region and robust IFN-ɤ and T cell responses (22, 23), we next addressed the role of ORF8 in the differential MHC-…”
BackgroundInfluentialSammartino, J. C., Cassaniti, I., Ferrari, A., Giardina, F., Ferrari, G., Zavaglio, F., Paolucci, S., Lilleri, D., Piralla, A., Baldanti, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10050703 · Cited by 9
“Coronaviruses, including SARS-CoV-2, develop many mutations that are often not detrimental for their biological behavior and their structures [13].”
BackgroundPotential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations
Tsai, M., Shih, W., Yang, Y., Lin, Y., Chang, G., Hsu, C., Yeh, R., Shu, L., Cheng, Y., Liu, H.-T., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112802 · Cited by 10
SARS‐CoV‐2 variants and spike mutations involved in second wave of COVID‐19 pandemic in India
Muttineni, R., Binitha, R. N., Putty, K., Marapakala, K., Sandra, K. P., Panyam, J., Aravind, V., Singh, S. M., Balachandran, S., Viroji Rao, S. T., et al. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14508 · Cited by 15
“Mutations P681R and P681Hare located in the polybasic S1/S2 furin cleavage site and were reported to enhance the fusogenic activity of the spike protein (Tao et al., 2021).”
BackgroundPhatarphekar, A., Reddy, G. E. C. V., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.026 · Cited by 9
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Saunders, N., Planas, D., Bolland, W., Rodriguez, C., Fourati, S., Buchrieser, J., Planchais, C., Prot, M., Staropoli, I., Guivel‐Benhassine, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103934 · Cited by 13
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11
“A detailed summary of the biological and clinical relevance of SARS-CoV-2 variants has recently been published [64].”
BackgroundChen, R.-R., Cao, G.-P., Song, X., Lu, M., Wang, M., Wang, X., Wang, M.-F., Wang, S.-Q., Wan, S., Yang, G., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02437-y · Cited by 11
Jamhuri, M., Irawan, M. I., Mukhlash, I., Iqbal, M., & Puspaningsih, N. N. T. (2025) · Systems and Soft Computing · doi:10.1016/j.sasc.2025.200195 · Cited by 8
Kabir, M. P., Mercier, É., Eid, W., Plaza‐Díaz, J., D’Aoust, P. M., Landgraff, C., Goodridge, L. D., Lawal, O. U., Wan, S., Hegazy, N., et al. (2025) · Eco-Environment & Health · doi:10.1016/j.eehl.2025.100135 · Cited by 8
(R)evolution of Viruses: Introduction to biothermodynamics of viruses
Popovic, M. E., Tadić, V. M., & Popović, M. (2024) · Virology · doi:10.1016/j.virol.2024.110319 · Cited by 7
Fajgenblat, M., Molenberghs, G., Verbeeck, J., Willem, L., Crèvecoeur, J., Faes, C., Hens, N., Deboosere, P., Verbeke, G. N., & Neyens, T. (2024) · Communications Medicine · doi:10.1038/s43856-024-00600-0 · Cited by 8
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Liang, L., Wang, B., Zhang, Q., Zhang, S., & Zhang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116900 · Cited by 8
Angulo-Aguado, M., Carrillo-Martínez, J. C., Contreras-Bravo, N. C., Morel, A., Abaunza, K. P., Usaquén, W., Fonseca, D. J., & Ortega‐Recalde, O. (2024) · Scientific Reports · doi:10.1038/s41598-024-57982-3 · Cited by 13
Ravi, V., Shamim, U., Khan, M. A., Swaminathan, A., Mishra, P., Rajender, S., Bharali, P., Chauhan, N. S., & Pandey, R. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294699 · Cited by 7
“BA.1 and BA.5 emerged with common mutations in the spike region (N501Y, E484K, Δ H69/V70) despite their different origins from South Africa and Botswana respectively, indicating convergent evolution (13, 19, 20).”
BackgroundGPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19
Marković, M., Ranin, J. T., Bukumirić, Z., Jerotić, D., Savic-Radojevic, A. R., Pljesa-Ercegovac, M. S., Djukic, T. I., Ercegovac, M., Ašanin, M., Milošević, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216151 · Cited by 8
Li, C., Chen, L., Li, L., & Chen, W. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106564 · Cited by 9
Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy
Gurukkalot, K., & Rajendran, V. (2023) · Current Microbiology · doi:10.1007/s00284-023-03366-1 · Cited by 10
“529) variants a significant concern [7-9].”
Lopez-Orozco, J., Fayad, N., Khan, J. Q., Felix-Lopez, A., Elaish, M., Rohamare, M., Sharma, M., Falzarano, D., Pelletier, J., Wilson, J. A., et al. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168170 · Cited by 8
“However, with the continuous emergence of variants of concern, the effectiveness of current vaccines and monoclonal antibodies that were designed against earlier strains of SARS-CoV-2, are significantly lower (reviewed in [7, 8]).”
Wang, Z., Li, D., Chen, Y., Sun, Y., Jin, C., Hu, C., Feng, Y., Su, J., Ren, L., Hao, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160283 · Cited by 8
“Above all, SARS-CoV-2 has developed into multiple variants, including Alpha, Beta, Gamma, Delta, Lambda and Omicron (1).”
BackgroundSars-escape network for escape prediction of SARS-COV-2
Bist, P. S., Tayara, H., & Chong, K. T. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad140 · Cited by 9
García‐Vega, M., Melgoza-González, E. A., Hernández‐Valenzuela, S., Hinojosa‐Trujillo, D., Reséndiz‐Sandoval, M., Llamas-Covarrubias, M. A., Loza-López, M., Valenzuela, O., Soto‐Gaxiola, A., Hernández‐Oñate, M. Á., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106562 · Cited by 9
“These variants are characterized by increased transmissibility, reduced vaccine efficacy, and increased risk of reinfection.(4,5) The latest variant described Omicron, carries over 30 mutations in the spike and possesses a high infectivity rate that provokes rapid global dissemination.”
Heggestad, J. T., Britton, R. J., Kinnamon, D., Liu, J., Anderson, J. G., Joh, D. Y., Quinn, Z., Fontes, C. M., Hucknall, A., Parks, R., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05180 · Cited by 8
Subregional origins of emerging SARS-CoV-2 variants during the second pandemic wave in Côte d’Ivoire
Anoh, E., Wayoro, O., Monemo, P., Belarbi, E., Sachse, A., Wilkinson, E., San, J. E., Leendertz, F., Diané, B., Calvignac-Spencer, S., et al. (2023) · Virus genes · doi:10.1007/s11262-023-01984-2 · Cited by 8
“The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is driven by the emergence and spread of virus variants with clinically relevant mutations that lead to increased transmissibility, virulence and immune escape abilities [1, 2].”
BackgroundKurokawa, M., Kurokawa, R., Lin, A. Y., Capizzano, A. A., Baba, A., Kim, J., Johnson, T. D., Srinivasan, A., & Moritani, T. (2022) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2022.12.003 · Cited by 9
Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19
Valenzuela-Fernández, A., Cabrera-Rodríguez, R., Ciuffreda, L., Pérez-Yanes, S., Estévez‐Herrera, J., González‐Montelongo, R., Alcoba-Flórez, J., Trujillo‐González, R., de Artola, D. G.-M., Gil-Campesino, H., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1052436 · Cited by 8
Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
Phoksawat, W., Nithichanon, A., Lerdsamran, H., Wongratanacheewin, S., Meesing, A., Pipattanaboon, C., Kanthawong, S., Aromseree, S., Yordpratum, U., Laohaviroj, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.017 · Cited by 8
“The pandemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a significant global public health concern [1], with global impacts on social-, economic- and health-inequalities [2].”
BackgroundCharacteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
Feng, X., Yu, D., Zhang, M., Li, X., Zou, Q., Ma, W., Han, J.-B., Xu, L., Yang, C., Qu, W., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.09.007 · Cited by 7
Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico
Castelán-Sánchez, H. G., Martínez-Castilla, L. P., Martinez, G. S., Torres-Flores, J. M., & López-Leal, G. (2022) · Virus Evolution · doi:10.1093/ve/veac109 · Cited by 13
Ye, Z., Fan, Y., Tang, K., Ong, C. P., Luo, C., Chung, H.-L., Leong, T.-L., Liang, R., Lui, W., Zhou, R., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72109 · Cited by 8
“Unlike the Alpha variant, the immune-evasive Beta and Gamma variants had no chance to become the predominant variant at the global scale [8].”
BackgroundAssessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival
Loucera, C., Pérez-Florido, J., Casimiro‐Soriguer, C. S., Ortuño, F. M., Carmona, R., Bostelmann, G., Martínez-González, L. J., Muñoyerro-Muñiz, D., Villegas, R., Rodríguez‐Baño, J., et al. (2022) · Viruses · doi:10.3390/v14091893 · Cited by 11
“Actually, the definition or variants of concern (VOC) or variants of interest (VOI) is proposed by the World Health Organization (WHO) [11], the Centers for Disease Control and Prevention (CDC) [28], and COVID-19 Genomics UK Consortium (COG-UK) [29] are based on observed transmissibility, greater severity of disease,…”
BackgroundTahsin, A., Ahmed, R., Bhattacharjee, P., Adiba, M., Saba, A. A., Yasmin, T., Chakraborty, S., Hasan, A. K. M. M., & Nabi, A. N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105903 · Cited by 9
“Like other RNA viruses, the SARS-CoV-2 has a high mutation rate, and this has caused the emergence of many variants of this virus since its identification [14].”
BackgroundSun, C., Yuan, R., Xie, C., Sun, J., Fang, X., Hu, Y., Yu, X., Liu, Z., Zeng, M., & Kang, Y. (2022) · Journal of Virology · doi:10.1128/jvi.00383-22 · Cited by 7
“Among the currently documented VOCs, the Beta, Gamma, Delta, and Omicron variants were reported to exhibit a significant capacity to escape neutralization by wild-type-elicited antibodies, and clinical investigations indicated that Beta, Omicron, and Delta variants possibly reduced the protective effect of vaccination…”
BackgroundAssessing COVID-19 vaccination strategies in varied demographics using an individual-based model
Ben-Zuk, N., Daon, Y., Sasson, A., Ben-Adi, D., Huppert, A., Nevo, D., & Obolski, U. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966756 · Cited by 6
“New variants of the SARS-CoV-2 are constantly evolving worldwide (7, 8); some have become the locally or globally predominant variants.”
BackgroundTalasaz, A. H., Sadeghipour, P., Mehdizadeh, K., Rad, N. K., Bikdeli, B., Lip, G. Y. H., & Harenberg, J. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1956-9641 · Cited by 10
Metadata
- Authors
- Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W.
- Affiliations
- Stanford Medicine (US)
- University of Cambridge (GB)
- Swarthmore College (US)
- Corresponding author
- Shafer, Robert W.
- Venue
- Nature Reviews Genetics
- Published
- 2021-09-17
- Volume
- 22
- Issue
- 12
- Pages
- 757-773
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- PMC
- PMC8447121
- OpenAlex
- W3199849883
- Cited by
- 1,009
- References
- 281
- Citations by year
- 2026: 43 · 2025: 90 · 2024: 170 · 2023: 251 · 2022: 415 · 2021: 38
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Reviews Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Works - Scholarship, Research, & Creative Expression (Swarthmore College) (submittedVersion)
- Funders
- University of Washington
- National Institute of Allergy and Infectious Diseases (R24AI136618)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, COVID-19 variants of concern, spike protein mutations, Alpha variant, Beta variant, Gamma variant, Delta variant, virus transmission, reinfection risk, neutralizing antibodies, vaccine effectiveness, herd immunity, viral replication fitness
- MeSH terms
- COVID-19, SARS-CoV-2, Epitopes, Biological Evolution, Humans, Mutation, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
